Literature DB >> 10502022

Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI).

J Ruof1, O Sangha, G Stucki.   

Abstract

OBJECTIVE: Transcultural adaptation of the two most widely used and accepted functional indices in ankylosing spondylitis, the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI).
METHODS: The instruments were translated and tested for internal consistency (Cronbach's coefficient alpha), test-retest reliability (intraclass correlation coefficient, ICC), construct validity (testing for association with Schober's test, finger floor distance, occiput wall distance, frequency and duration of awakenings at night, and a visual analog scale pain), and responsiveness (standardized response mean, SRM).
RESULTS: The study sample consisted of 72 patients of a randomized, controlled clinical trial receiving either Diclofenac or placebo. Visual assessment of distribution patterns revealed a ceiling effect of both instruments. Both questionnaires had a high internal consistency (Cronbach alpha: 0.81 [BASFI], 0.85 [D-FI] and a high test-retest reliability (ICC: 0.92 [BASFI], 0.89 [D-FI]). The limited responsiveness to Diclofenac treatment (SRM: 0.46 [BASFI], 0. 33 [D-FI]) may be related to the selected study sample. The BASFI was significantly correlated with all tested validation parameters. The D-FI was only significantly correlated with finger floor distance, occiput wall distance, and duration of awakenings at night.
CONCLUSION: The transculturally adapted version of both functional indices are valid, reliable, and internally consistent. Because of psychometric advantages, the BASFI may be preferred in clinical trial settings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502022     DOI: 10.1007/s003930050174

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  14 in total

1.  Translation and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI) for use in Ukraine.

Authors:  Oleg Nadashkevich; Oleksiy Masyk
Journal:  Clin Rheumatol       Date:  2011-04-15       Impact factor: 2.980

Review 2.  [Self-monitoring in inflammatory rheumatic diseases].

Authors:  C Kampling; G Chehab; M Schneider; J G Richter
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

3.  High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study.

Authors:  Joerg C Henes; Eva Ziupa; Michael Eisfelder; Annette Adamczyk; Bjoern Knaudt; Felix Jacobs; Juergen Lux; Stefan Schanz; Gerhard Fierlbeck; Daniel Spira; Marius Horger; Lothar Kanz; Ina Koetter
Journal:  Rheumatol Int       Date:  2013-10-10       Impact factor: 2.631

4.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

5.  Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis.

Authors:  Samira Rostom; Karima Benbouaaza; Bouchra Amine; Rachid Bahiri; Yousra Ibn Yacoub; Sanae Ali Ou Alla; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

Review 6.  [Outcome parameters in ankylosing spondylitis].

Authors:  H Haibel; M Rudwaleit; J Sieper
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

7.  Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis.

Authors:  Katayoon Bidad; Sasan Fallahi; Mahdi Mahmoudi; Ahmadreza Jamshidi; Elham Farhadi; Alipasha Meysamie; Mohammad Hossein Nicknam
Journal:  Rheumatol Int       Date:  2011-11-20       Impact factor: 2.631

8.  Evaluation of the Turkish version of the Dougados functional index in ankylosing spondylitis.

Authors:  Huseyin T E Ozer; Tunay Sarpel; Bozkurt Gulek; Z Nazan Alparslan; Eren Erken
Journal:  Rheumatol Int       Date:  2005-03-02       Impact factor: 2.631

9.  Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?

Authors:  Siddharth Bethi; Abhijit Dasgupta; Michael H Weisman; Thomas J Learch; Lianne S Gensler; John C Davis; John D Reveille; Michael M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

10.  The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity.

Authors:  Altinay Goksel Karatepe; Yesim Akkoc; Servet Akar; Yesim Kirazli; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2004-07-10       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.